LUNG CANCER

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the prevalence of patients with non-driver non–small cell lung cancer.

Corey Langer, MD, provides details on the goals and implications of the KEYNOTE-021 trial. Moreover, he discusses the current arena in NSCLC treatment and the obstacles that remain in treating patients without driver mutations effectively.

A Case of Metastatic ALK-Rearranged Non-Small Cell Lung Cancer

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

The investigators discuss their findings that demonstrate patients with previous radiotherapy experienced significantly longer PFS and OS with pembrolizumab treatment versus those with no previous radiotherapy.

David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses the combination of CTLA-4 agents with PD-1 and PD-L1 agents for the treatment of lung cancer.

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses pseudoprogression in lung cancer.

Roy S. Herbst, MD, PhD, discusses how the therapeutic paradigm will continue to evolve in the next few years for non–small cell lung cancer, with an increased emphasis on rational combinations and biomarkers.

David R. Gandara, MD, discusses toxicity management with the combination of dabrafenib and trametinib in non–small cell lung cancer.

A supplemental new drug application (sNDA) for alectinib (Alecensa) has been granted a priority review by the FDA for the frontline treatment of patients with <em>ALK</em>-positive locally advanced or metastatic non&ndash;small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation&nbsp;ALK inhibitor.

A look back at all the FDA news that occurred in July.

ALK-Translocated Non-Small Cell Lung Cancer With Bone Metastases

During the 2017 ESMO Congress, to be held September 8-12 in Madrid, Spain, the European Society for Medical Oncology (ESMO) will award 4 oncologists with its distinguished annual awards:

Durvalumab (Imfinzi) has been granted a breakthrough therapy designation by the FDA to treat patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation.

Progression-free survival (PFS) was not improved with frontline durvalumab (Imfinzi), either in combination with tremelimumab or as a single agent,&nbsp;in patients with stage IV metastatic non&ndash;small cell lung cancer (NSCLC), compared with standard platinum-based chemotherapy.

Supplemental Biologics License Applications (sBLAs) were sent to and accepted by the FDA for a new dosing schedule for nivolumab (Opdivo) across all of the agent&#39;s indications as a montherapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.&nbsp;

The European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use (CHMP) has given its support on indications for atezolizumab (Tecentriq) in non&ndash;small cell lung cancer (NSCLC) and urothelial carcinoma.&nbsp;